A vs DGX
A: A diversified healthcare and life sciences company providing analytical instruments, software, and services for pharmaceutical, chemical, and clinical diagnostics laboratories worldwide. DGX: A leading national provider of diagnostic testing and medical insights, delivering clinical laboratory services through an extensive network of patient centers and hospitals.
Side-by-side fundamentals
| Metric | A | DGX | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $137.89 | $231.84 | |
| Market cap as of 2026-07-31 | $38.9B | $25.8B | |
| P/E as of 2026-07-31 | 27.58 | 24.30 | DGX lower |
| PEG as of 2026-07-31 | 3.24 | 2.41 | DGX lower |
| Net margin as of 2026-07-31 | +19.6% | +9.2% | A higher |
| Gross margin as of 2026-07-31 | +52.9% | +33.2% | A higher |
| Operating margin as of 2026-07-31 | +21.5% | +14.1% | A higher |
| ROE as of 2026-07-31 | +20.8% | +14.5% | A higher |
| ROA as of 2026-07-31 | +11.1% | +6.4% | A higher |
| Debt / equity as of 2026-07-31 | 0.47 | 0.75 | A lower |
| Revenue growth (YoY) as of 2026-07-31 | +9.1% | +9.9% | DGX higher |
| Revenue CAGR (3y) SEC XBRL | +0.5% | +3.7% | DGX higher |
| Dividend yield as of 2026-07-31 | +0.7% | +1.5% | DGX higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-07-31 | 1.23 | 0.54 | |
| 1-year return as of 2026-07-27 close | +14.7% | +37.5% | DGX higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.